191846-77-2Relevant articles and documents
PYRROLOBENZODIAZEPINE PRODRUGS AND ANTIBODY CONJUGATES THEREOF
-
Page/Page column 176; 177, (2018/03/06)
The invention relates generally to pyrrolobenzodiazepine monomer and dimer prodrugs having a glutathione-activated disulfide prodrug moiety, a DT-diaphorase-activated quinone prodrug moiety or a reactive oxygen species-activated aryl boronic acid or aryl boronic ester prodrug moiety. The invention further relates to pyrrolobenzodiazepine prodrug dimer-antibody conjugates.
INDQ/NO, a bioreductively activated nitric oxide prodrug
Sharma, Kavita,Iyer, Aishwarya,Sengupta, Kundan,Chakrapani, Harinath
, p. 2636 - 2639 (2013/07/19)
The design, synthesis, and development of INDQ/NO, a novel nitric oxide (NO) prodrug targeted by a bioreductive trigger, are described. INDQ/NO, an indolequinone-diazeniumdiolate is found to be metabolized to produce NO by DT-diaphorase, a bioreductive enzyme that is overexpressed in certain cancers and hypoxic tumors. Cell-based assays revealed that INDQ/NO induces DNA damage and is a potent inhibitor of cancer cell proliferation.
2-cyclopropylindoloquinones and their analogues as bioreductively activated antitumor agents: Structure-activity in vitro and efficacy in vivo
Naylor, Matthew A.,Jaffar, Mohammed,Nolan, John,Stephens, Miriam A.,Butler, Susan,Patel, Kantilal B.,Everett, Steven A.,Adams, Gerald E.,Stratford, Ian J.
, p. 2335 - 2346 (2007/10/03)
A series of 2-cycloalkyl- and 2-alkyl-3-(hydroxymethyl)-1- methylindoloquinones and corresponding carbamates have been synthesized and substituted in the 5-position with a variety of substituted and unsubstituted aziridines. Cytotoxicity against hypoxic c